Management of Acne: Efficacy of Sarecycline in a Chinese Cohort

Recent findings from a phase 3 clinical trial have shed light on the therapeutic potential of sarecycline for the management of moderate-to-severe acne vulgaris among a cohort of 391 Chinese patients aged 9 to 45. The double-blind, placebo-controlled study spanned 12 weeks and assessed sarecycline's ability to reduce inflammatory lesions associated with acne.

Results indicated a statistically significant reduction in facial inflammatory lesions, with participants on sarecycline showing a 73.2% reduction in lesion count, compared with 46.0% in the placebo group. Noteworthy improvements were observed as early as week 3, suggesting a rapid onset of action.

Follow-up data indicated that participants who experienced lesion recurrence were successfully managed with additional courses of sarecycline, supporting its sustained efficacy and safety profile. These findings reinforce sarecycline as a formidable therapeutic approach for acne vulgaris in the Chinese population, meriting further investigation into its long-term effects and potential role in acne management strategies.

Click HERE for more info. 

Elevate-Derm Alliance Editorial Committee